ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Philadelphia, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Food Hypersensitivity
Hidradenitis
Hidradenitis Suppurativa
Hypersensitivity
Pruritus

Eczema trials near Philadelphia, PA, USA:

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...

Active, not recruiting
Eczema Atopic Dermatitis
Eczema, Atopic
Drug: Placebo
Drug: Camoteskimab

Phase 2

Apollo Therapeutics

Philadelphia, Pennsylvania, United States and 35 other locations

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...

Active, not recruiting
Atopic Dermatitis
Drug: Dupilumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Philadelphia, Pennsylvania, United States and 83 other locations

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: PF-07275315

Phase 2

Pfizer
Pfizer

Philadelphia, Pennsylvania, United States and 96 other locations

24-week study of 20 atopic dermatitis patients who have been treated with dupilumab will receive Tralokinumab 600mg at week 0 followed by 300mg Q2W f...

Active, not recruiting
Atopic Dermatitis
Drug: tralokinumab

Phase 4

Psoriasis Treatment Center of Central New Jersey

East Windsor, New Jersey, United States

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherap...

Enrolling
Atopic Dermatitis
Drug: Dupixent

Phase 4

Psoriasis Treatment Center of Central New Jersey

East Windsor, New Jersey, United States

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients wi...

Enrolling
Atopic Dermatitis
Drug: BxC-I17e
Drug: Placebo

Phase 1

Brexogen

Philadelphia, Pennsylvania, United States and 2 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Philadelphia, Pennsylvania, United States and 536 other locations

Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD

Enrolling
Atopic Dermatitis
Drug: Soquelitinib
Drug: Placebo

Phase 1

Corvus Pharmaceuticals
Corvus Pharmaceuticals

Philadelphia, Pennsylvania, United States and 15 other locations

The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy...

Active, not recruiting
Atopic Dermatitis
Drug: Placebo
Biological: UCB1381

Phase 1, Phase 2

UCB
UCB

Philadelphia, Pennsylvania, United States and 15 other locations

assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult pa...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A

Phase 3

AbbVie
AbbVie

Philadelphia, Pennsylvania, United States and 95 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems